Fairvalue-Calculator Fairvalue-Calculator
EN DE

ACRO Biomedical Co (6748) Fair Value & Analysis

Healthcare · TW · Market cap 8.6B TWD

Price132.00 TWD
Fair Value46.53 TWD
Upside-64.8%
Quality95/100
Evidence: Low Range 34.90 TWD – 58.16 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

ACRO Biomedical Co (6748) currently trades at 132.00 TWD, while our model-based Fair Value estimate is 46.53 TWD — implying the stock looks roughly 64.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

ACRO Biomedical Co., Ltd. develops medical-grade regenerative biomaterials. The company offers products in the areas of wound care, orthopedics, dentistry, ophthalmology, cosmetic micro plastic surgery, beauty and eye care, and tissue engineering and regenerative medicines. The company was founded in 2014 and is based in Kaohsiung, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is ACRO Biomedical Co (6748) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 46.53 TWD versus a price of 132.00 TWD — about −65% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6748?
Our 21-model fair value for ACRO Biomedical Co is 46.53 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 132.00 TWD.
What is the quality score of 6748?
ACRO Biomedical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.